M Soledad Cepeda

List of Publications by Year
in descending order

55 papers	**2,206** citations	430442 **18** h-index	223531 **46** g-index
56 all docs	**56** docs citations	**56** times ranked	**3628** citing authors

#	Article	IF	Citations
1	Comparison of Logistic Regression versus Propensity Score When the Number of Events Is Low and There Are Multiple Confounders. American Journal of Epidemiology, 2003, 158, 280-287.	1.6	691
2	What decline in pain intensity is meaningful to patients with acute pain?. Pain, 2003, 105, 151-157.	2.0	404
3	Opioid Shopping Behavior: How Often, How Soon, Which Drugs, and What Payment Method. Journal of Clinical Pharmacology, 2013, 53, 112-117.	1.0	86
4	Assessing Opioid Shopping Behaviour. Drug Safety, 2012, 35, 325-334.	1.4	71
5	Microbiome-Gut-Brain Axis: Probiotics and Their Association With Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 39-44.	0.9	67
6	Depression Is Associated With High Levels of C-Reactive Protein and Low Levels of Fractional Exhaled Nitric Oxide. Journal of Clinical Psychiatry, 2016, 77, 1666-1671.	1.1	66
7	Placebo Response Changes Depending on the Neuropathic Pain Syndrome: Results of a Systematic Review and Meta-Analysis. Pain Medicine, 2012, 13, 575-595.	0.9	64
8	Finding factors that predict treatment-resistant depression: Results of a cohort study. Depression and Anxiety, 2018, 35, 668-673.	2.0	54
9	Comparison of the Risks of Opioid Abuse or Dependence Between Tapentadol and Oxycodone: Results From a Cohort Study. Journal of Pain, 2013, 14, 1227-1241.	0.7	52
10	Clinical Relevance of Sleep Duration: Results from a Cross-Sectional Analysis Using NHANES. Journal of Clinical Sleep Medicine, 2016, 12, 813-819.	1.4	43
11	Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse. Clinical Journal of Pain, 2014, 30, 1051-1056.	0.8	42
12	Comparison of Opioid Doctor Shopping for Tapentadol andÂOxycodone: A Cohort Study. Journal of Pain, 2013, 14, 158-164.	0.7	39
13	Association of flossing/interâ€dental cleaning and periodontitis in adults. Journal of Clinical Periodontology, 2017, 44, 866-871.	2.3	37
14	Distance Traveled and Frequency of Interstate Opioid Dispensing in Opioid Shoppers and Nonshoppers. Journal of Pain, 2013, 14, 1158-1161.	0.7	33
15	Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics. Depression and Anxiety, 2018, 35, 220-228.	2.0	33
16	ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes. Pain Medicine, 2017, 18, 78-85.	0.9	30
17	Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019. BMC Psychiatry, 2020, 20, 4.	1.1	30
18	Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurology, 2020, 20, 296.	0.8	23

#	Article	IF	Citations
19	Doctor shopping for medications used in the treatment of attention deficit hyperactivity disorder: shoppers often pay in cash and cross state lines. American Journal of Drug and Alcohol Abuse, 2015, 41, 226-229.	1.1	21
20	Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon, 2018, 4, e00707.	1.4	19
21	Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson's Drug Discovery. Clinical Drug Investigation, 2019, 39, 1067-1075.	1.1	19
22	Low levels of cholesterol and the cholesterol type are not associated with depression: Results of a cross-sectional NHANES study. Journal of Clinical Lipidology, 2020, 14, 515-521.	0.6	19
23	Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Services and Outcomes Research Methodology, 2013, 13, 58-67.	0.8	18
24	The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 2000, 9, 103-104.	0.9	17
25	Treatment resistant depression in women with peripartum depression. BMC Pregnancy and Childbirth, 2019, 19, 323.	0.9	17
26	Use of ClinicalTrials.gov to Estimate Condition-Specific Nocebo Effects and Other Factors Affecting Outcomes of Analgesic Trials. Journal of Pain, 2013, 14, 405-411.	0.7	16
27	From ClinicalTrials.gov trial registry to an analysis-ready database of clinical trial results. Clinical Trials, 2013, 10, 347-348.	0.7	14
28	Shopping Behavior for ADHD Drugs: Results of a Cohort Study in a Pharmacy Database. Drugs in R and D, 2014, 14, 205-211.	1.1	14
29	Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 862-870.	1.8	13
30	Frequency of rehospitalization after hospitalization for suicidal ideation or suicidal behavior in patients with depression. Psychiatry Research, 2020, 285, 112810.	1.7	13
31	Characteristics of prescribers whose patients shop for opioids: Results from a cohort study. Journal of Opioid Management, 2012, 8, 285-291.	0.2	12
32	Possible Opioid Shopping and its Correlates. Clinical Journal of Pain, 2017, 33, 976-982.	0.8	11
33	Effect of Tapentadol Extended Release on Productivity. Clinical Journal of Pain, 2012, 28, 8-13.	0.8	10
34	<p>An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016â€"2018</p>. Journal of Pain Research, 2020, Volume 13, 2431-2442.	0.8	10
35	At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study. Depression and Anxiety, 2021, 38, 521-527.	2.0	9
36	Use of Adjectives in Abstracts when Reporting Results of Randomized, Controlled Trials from Industry and Academia. Drugs in R and D, 2015, 15, 85-139.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Medical record-based ascertainment of behaviors suggestive of opioid misuse, diversion, abuse, and/or addiction among individuals showing evidence of doctor/pharmacy shopping . Journal of Pain Research, 2019, Volume 12, 2291-2303.	0.8	8
38	Treatment patterns of patients diagnosed with major depressive disorder and suicidal ideation or attempt: a U.S. population-based study utilizing real-world data. BMC Psychiatry, 2021, 21, 608.	1.1	8
39	Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients. Postgraduate Medicine, 2020, 132, 44-51.	0.9	7
40	<p>The Association Between Doctor and Pharmacy Shopping and Self-Reported Misuse and Abuse of Prescription Opioids: A Survey Study</p>. Journal of Pain Research, 2020, Volume 13, 689-701.	0.8	7
41	Exploring real-world evidence to uncover unknown drug benefits and support the discovery of new treatment targets for depressive and bipolar disorders. Journal of Affective Disorders, 2021, 290, 324-333.	2.0	7
42	Assessing the impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategies on opioid prescription volume. Journal of Opioid Management, 2017, 13, 157-168.	0.2	7
43	Using Sherlock and ClinicalTrials.gov Data to Understand Nocebo Effects and Adverse Event Dropout Rates in the Placebo Arm. Journal of Pain, 2013, 14, 999.	0.7	6
44	Pain Qualities and Satisfaction with Therapy: A Survey of Subjects with Neuropathic Pain. Pain Medicine, 2013, 14, 1745-1756.	0.9	6
45	Comments to Drs. Bahji, Vazquez, and Zarate. Journal of Affective Disorders, 2021, 283, 262-264.	2.0	5
46	Individuals who develop drug-resistant epilepsy within a year after initial diagnosis have higher burden of mental and physical diseases one-year prior to epilepsy diagnosis as compared to those whose seizures were controlled during the same interval. Epilepsy and Behavior, 2021, 123, 108243.	0.9	4
47	Risk Factors for Interstitial Cystitis in the General Population and in Individuals With Depression. International Neurourology Journal, 2019, 23, 40-45.	0.5	4
48	Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data . Substance Abuse and Rehabilitation, 2019, Volume 10, 47-55.	1.6	3
49	<p>Incidence of Opioid Overdose Among Patients Using ER/LA Opioid Analgesics Before and After Implementation of the Class-Wide Opioid Risk Evaluation and Mitigation Strategy</p>. Journal of Pain Research, 2020, Volume 13, 157-169.	0.8	3
50	Medical Conditions Predictive of Self-Reported Poor Health: Retrospective Cohort Study. JMIR Public Health and Surveillance, 2020, 6, e13018.	1.2	3
51	Patient Knowledge of Safe Use of ER/LA Opioid Analgesics Following Implementation of the Class-Wide REMS: A Survey Study. Patient Preference and Adherence, 2021, Volume 15, 431-442.	0.8	2
52	No debate on the minimal decline in pain intensity that patients can discern. American Journal of Emergency Medicine, 2006, 24, 391-392.	0.7	1
53	Identifying Anticipated Events of Future Clinical Trials by Leveraging Data from the Placebo Arms of Completed Trials. Therapeutic Innovation and Regulatory Science, 2021, 55, 454-461.	0.8	0
54	Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists. CNS Drugs, 2021, 35, 243-251.	2.7	0

#	Article	IF	Citations
55	Revealing Unknown Benefits of Existing Medications to Aid the Discovery of New Treatments for Post‑Traumatic Stress Disorder. Psychiatric Research and Clinical Practice, 2022, 4, 12-20.	1.3	0